Cancer became recently the leading cause of death in industrialized countries. Even
though standard treatments achieve significant effects in growth inhibition and tumor
elimination, they cause severe side effects as most of the applied drugs exhibit only
minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells
without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface
receptors, which bind peptides are frequently overexpressed on cancer cells and can
therefore be considered as promising targets for selective tumor therapy. In this review,
the benefits of peptides as tumor homing agents are presented and an overview of the
most commonly addressed peptide receptors is given. A special focus was set on the
bombesin receptor family and the neuropeptide Y receptor family. In the second part, the
specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures
as an essential component of PDC are outlined. Furthermore, different drug cargos
are presented including classical and recent toxic agents as well as radionuclides for
diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy
as advanced targeted cancer therapy is introduced and past and recent developments
are reviewed.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84526 |
| Date | 03 April 2023 |
| Creators | Hoppenz, Paul, Els-Heindl, Sylvia, Beck-Sickinger, Annette G. |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 2296-2646, 571 |
Page generated in 0.0017 seconds